The positive outcome of the Phase 2 study for brepocitinib in NIU treatment indicates a strong potential for future revenue growth from this drug, enhancing investor confidence in Roivant Sciences. The share repurchase program, particularly the buyback from Sumitomo Pharma, is likely to be viewed positively by the market as it reflects the company's confidence in its own stock and financial health, contributing to the 5.37% increase in ROIV shares. This combination of successful drug development and strategic financial actions suggests a positive short-term impact on ROIV's stock price.